Table 1. Demographic and clinical characteristics of study participants.
Characteristic | Active GCA (n=30) | Inactive GCA (n=30) | Non-disease controls (n=30) |
Age (years) | |||
Mean±SD | 70.5±9.3 | 70.9±9.3 | 70.0±7.8 |
IQR† (Q1, Q3) | (63.7, 77.2) | (64.1, 70.9) | (65.3, 72.8) |
Sex | |||
Female, n (%) | 23 (76.7) | 23 (76.7) | 23 (76.7) |
Male, n (%) | 7 (23.3) | 7 (23.3) | 7 (23.3) |
Race | |||
White, n (%) | 29 (96.7) | 29 (96.7) | 30 (100.0) |
Asian, n (%) | 1 (3.3) | 1 (3.3) | 0 (0.0) |
Smokers, n (%) | 17 (56.7) | 17 (56.7) | 10 (33.3) |
Unknown, n | 0 | 0 | 1 |
Body mass index | |||
Mean±SD | 27.2±5.6 | 27.6±6.0 | 24.2±5.2 |
IQR (Q1, Q3) | (23.1, 31.0) | (22.7, 31.1) | (20.6, 27.5) |
Unknown, n | 4 | 5 | 1 |
C reactive protein (mg/dL) | |||
Mean±SD | 3.2±2.6 | 0.5±0.3 | N/A |
IQR (Q1, Q3) | (1.4, 3.7) | (0.3, 0.8) | |
Disease stage in active GCA group | |||
Early disease course§, n (%) | 24 (80) | ||
Disease duration (months) | N/A | N/A | |
Mean±SD | 7.6±11.9 | ||
IQR (Q1, Q3) | (0.4, 10.8) | ||
Flare history, n (%) | 9 (27.3) | ||
Physician global assessment | |||
Mean±SD | 4.4±2.1 | 0.0±0.0 | N/A |
Treatment | |||
Prednisone, n (%) | 22 (73.3) | 21 (70.0) | N/A |
Prednisone dose (mg/day) | |||
Median | 10 | 10 | |
IQR | (2.75–26) | (8.75–10.0) | |
Unknown, n | 11 | 9 | |
Aspirin/clopidogrel, n (%) | 19 (63.3) | 17 (56.7) | |
Aspirin low dose (mg/day) | 325.0 | 325.0 | |
Abatacept/lefluomide/methotrexate, n (%) | 5 (16.7) | 9 (30.0) | |
Statin, n (%) | 4 (13.3) | 5 (16.7) | |
Oestrogen, n (%) | 1 (3.3) | 0 (0.0) |
IQR, interquartile range.
Within 1 year of initial GCA diagnosis.
GCAgiant cell arteritisN/Anot applicable